Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M124,454Revenue (TTM) $M22,156Net Margin (%)32.6Altman Z-Score2.8
Enterprise Value $M124,021EPS (TTM) $9.5Operating Margin %39.9Piotroski F-Score7
P/E(ttm)17.6Beneish M-Score-2.5Pre-tax Margin (%)37.7Higher ROA y-yY
Price/Book4.310-y EBITDA Growth Rate %11.6Quick Ratio4.7Cash flow > EarningsY
Price/Sales5.75-y EBITDA Growth Rate %15.8Current Ratio5.0Lower Leverage y-yN
Price/Free Cash Flow14.4y-y EBITDA Growth Rate %23.9ROA % (ttm)10.1Higher Current Ratio y-yN
Dividend Yield %2.2PEG1.1ROE % (ttm)26.0Less Shares Outstanding y-yY
Payout Ratio %36.0Shares Outstanding M751ROIC % (ttm)26.5Gross Margin Increase y-yY

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNFirst Eagle Investment 2016-03-31 Add0.11%$140.9 - $162.33
($148.76)
$ 165.6711%Add 28.98%1,235,154
AMGNJoel Greenblatt 2016-03-31 Add0.08%$140.9 - $162.33
($148.76)
$ 165.6711%Add 16.86%323,405
AMGNVanguard Health Care Fund 2016-03-31 Reduce-0.05%$140.9 - $162.33
($148.76)
$ 165.6711%Reduce -2.91%5,241,755
AMGNGeorge Soros 2016-03-31 Sold Out -0.01%$140.9 - $162.33
($148.76)
$ 165.6711%Sold Out0
AMGNKen Fisher 2016-03-31 Reduce-0.01%$140.9 - $162.33
($148.76)
$ 165.6711%Reduce -17.38%112,693
AMGNDodge & Cox 2016-03-31 Reduce$140.9 - $162.33
($148.76)
$ 165.6711%Reduce -6.62%43,557
AMGNMario Gabelli 2016-03-31 Reduce$140.9 - $162.33
($148.76)
$ 165.6711%Reduce -5.02%37,210
AMGNRuane Cunniff 2016-03-31 Sold Out $140.9 - $162.33
($148.76)
$ 165.6711%Sold Out0
AMGNJoel Greenblatt 2015-12-31 Reduce-0.18%$141.22 - $164.58
($157.65)
$ 165.675%Reduce -31.85%276,751
AMGNFirst Eagle Investment 2015-12-31 Add0.17%$141.22 - $164.58
($157.65)
$ 165.675%Add 73.61%957,656
AMGNVanguard Health Care Fund 2015-12-31 Reduce-0.05%$141.22 - $164.58
($157.65)
$ 165.675%Reduce -3.25%5,398,985
AMGNGeorge Soros 2015-12-31 Add0.01%$141.22 - $164.58
($157.65)
$ 165.675%Add 109.52%4,400
AMGNDodge & Cox 2015-12-31 Reduce$141.22 - $164.58
($157.65)
$ 165.675%Reduce -3.52%46,644
AMGNMario Gabelli 2015-12-31 Reduce$141.22 - $164.58
($157.65)
$ 165.675%Reduce -3.39%39,175
AMGNKen Fisher 2015-12-31 Add$141.22 - $164.58
($157.46)
$ 165.675%Add 2.07%136,400
AMGNJoel Greenblatt 2015-09-30 Reduce-0.07%$132.24 - $176.59
($157.63)
$ 165.675%Reduce -11.55%406,106
AMGNFirst Eagle Investment 2015-09-30 Add0.04%$132.24 - $176.59
($157.63)
$ 165.675%Add 22.77%551,600
AMGNKen Fisher 2015-09-30 Reduce-0.01%$132.24 - $176.59
($157.63)
$ 165.675%Reduce -13.84%133,632
AMGNDodge & Cox 2015-09-30 Reduce$132.24 - $176.59
($157.63)
$ 165.675%Reduce -4.84%48,344
AMGNGeorge Soros 2015-09-30 Buy $132.24 - $176.59
($157.63)
$ 165.675%New holding2,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Balachandran MadhavanEVP, Operations 2016-05-04Sell30,000$154.127.49view
Harper Sean EEVP, Research & Development 2016-04-29Sell21,875$157.994.86view
BALTIMORE DAVIDDirector 2016-04-29Sell3,312$157.215.38view
Bradway Robert AChairman, CEO and President 2016-03-02Sell20,000$146.4813.1view
de Carbonnel FrancoisDirector 2015-08-31Sell5,000$153.847.69view
Hassan FredDirector 2015-08-19Buy3,010$166.63-0.58view
PELHAM JUDITH CDirector 2015-07-31Sell5,035$180.4-8.17view
Patton Cynthia MSVP & CCO 2015-06-02Sell4,530$157.065.48view
Balachandran MadhavanEVP, Operations 2015-05-07Sell21,750$157.874.94view
Tross Stuart ASVP, Human Resources 2015-04-23Sell3,012$169.31-2.15view

Press Releases about AMGN :

Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
    John Buckingham Touts Apple, Gilead, Amgen May 11 2016 
    Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
    Dan Loeb's Third Point Portfolio Highly Concentrated Apr 01 2016 
    Daniel Loeb's Third Point Portfolio Highly Concentrated Mar 31 2016 
    Citigroup, Amgen Are Trading With Wide Margin of Safety Mar 30 2016 
    Amgen: Should I Just Sit and Wait? Mar 18 2016 
    Gilead, Johnson & Johnson or Roche? Feb 11 2016 
    Plenty of Opportunity to Buy Individual Stocks: John Buckingham Feb 02 2016 
    Alan Fournier Sells GM, Buys Molson Coors Brewing Jan 03 2016 

    More From Other Websites
    Great Stocks With Rising Dividends Jul 23 2016
    Fourth Straight Week Of Gains; Buckle Up For Earnings Jul 22 2016
    Amgen Announces 2016 Third Quarter Dividend Jul 22 2016
    Amgen Announces Webcast Of 2016 Second Quarter Financial Results Jul 22 2016
    Pharma Industry Outlook: Fundamentals Remain Strong Jul 22 2016
    Amgen Announces Webcast Of 2016 Second Quarter Financial Results Jul 22 2016
    Amgen Announces 2016 Third Quarter Dividend Jul 22 2016
    Amgen 2Q Earnings: Here's What To Expect Jul 22 2016
    Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA Jul 22 2016
    2:30 am Amgen and UCB submit Biologics License Application to the FDA for Romosozumab Jul 22 2016
    Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA Jul 22 2016
    Amgen and Allergan Study Finds Biosimilar Comparable to Herceptin Jul 21 2016
    Amgen (AMGN) Stock Rises on 'Non-Inferior' Late-Stage Trial Results Jul 21 2016
    Amgen, Allergan biosimilar found as effective as Roche cancer drug Jul 21 2016
    Biogen: CEO Departing; Is This Drug Maker In Play? Jul 21 2016
    The Zacks Analyst Blog Highlights: Zafgen, Celgene, Amgen, AbbVie and Biogen Jul 21 2016
    Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With... Jul 21 2016
    Amgen Announces Settlement Of Securities Litigation Jul 20 2016
    Biotech Stock Roundup: Celgene in Immuno-Oncology Deal, Zafgen Drops Lead Drug Jul 20 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)